A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.

The CYP19 gene encodes for aromatase (P450arom), a key steroidogenic enzyme that catalyzes the final step of estrogen biosynthesis. Apart from rare mutations in CYP19 which result in severe phenotypes associated with estrogen insufficiency, little is known about whether common variation in CYP19 is associated with risk of hormone-related diseases. In this study, we employed a haplotype-based approach to search for common disease-associated variants in this candidate breast cancer susceptibility gene among African-American, Hawaiian, Japanese, Latina and White women in the Multiethnic Cohort Study (MEC). We utilized 74 densely spaced single-nucleotide polymorphisms (SNPs) (one every approximately 2.6 kb) spanning 189.4 kb of the CYP19 locus to characterize linkage disequilibrium (LD) and haplotype patterns among 69-70 individuals from each ethnic population. We detected four regions of strong LD (blocks 1-4) that were quite closely conserved across populations. Within each block there was a limited diversity of common haplotypes (5 to 10 with a frequency >/=5%) and most haplotypes were observed to be shared across populations. Twenty-five haplotype-tagging SNPs (htSNPs) were selected to predict the common haplotypes with high probability (average Rh2=0.92) and genotyped in a breast cancer case-control study in the MEC (cases, n=1355; controls, n=2580). We first performed global tests for differences in risk according to the common haplotypes and observed significant haplotype-effects in block 2 [P=0.01; haplotypes 2b (OR=1.23; 95% CI, 1.07-1.40), 2d (OR=1.28; 95% CI, 1.01-1.62)]. We also found a common long-range haplotype comprised of block-specific haplotypes 2b and 3c to be associated with increased risk of breast cancer (haplotype 2b-3c: OR=1.31; 95% CI, 1.11-1.54). Our findings suggest the hypothesis that women with the long-range CYP19 haplotype 2b-3c may be carriers of a predisposing breast cancer susceptibility allele.

[1]  N. Harada,et al.  Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. , 1996, The Journal of clinical endocrinology and metabolism.

[2]  D. Spiegelman,et al.  No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  Rod J. Rohrich,et al.  Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. , 1996, The Journal of clinical endocrinology and metabolism.

[4]  Christopher A. Haiman,et al.  Choosing Haplotype-Tagging SNPS Based on Unphased Genotype Data Using a Preliminary Sample of Unrelated Subjects with an Example from the Multiethnic Cohort Study , 2003, Human Heredity.

[5]  Y. Miyoshi,et al.  Breast cancer risk associated with polymorphism in CYP19 in Japanese women , 2000, International journal of cancer.

[6]  J. Mathis,et al.  Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. , 1989, The Journal of biological chemistry.

[7]  D. Noh,et al.  Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women , 2003, British Journal of Cancer.

[8]  N. Harada,et al.  Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  W. Willett,et al.  A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk , 2000, International journal of cancer.

[10]  B. Henderson,et al.  Hormonal carcinogenesis. , 2000, Carcinogenesis.

[11]  G. Séralini,et al.  Aromatase and breast cancer: W39R, an inactive protein. , 2002, European journal of endocrinology.

[12]  Frank Dudbridge,et al.  Haplotype tagging for the identification of common disease genes , 2001, Nature Genetics.

[13]  M. Pike,et al.  Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  Lon R. Cardon,et al.  Efficient selective screening of haplotype tag SNPs , 2003, Bioinform..

[15]  Daniel O. Stram,et al.  Modeling and E-M Estimation of Haplotype-Specific Relative Risks from Genotype Data for a Case-Control Study of Unrelated Individuals , 2003, Human Heredity.

[16]  Ji-ping Wang,et al.  In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. , 1998, Cancer research.

[17]  N. Harada,et al.  Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. , 1994, Human pathology.

[18]  D O Stram,et al.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. , 2000, American journal of epidemiology.

[19]  N. Harada,et al.  Cloning of a complete cDNA encoding human aromatase: immunochemical identification and sequence analysis. , 1988, Biochemical and biophysical research communications.

[20]  C. Mendelson,et al.  Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. , 1991, The Journal of biological chemistry.

[21]  M. Waterman,et al.  A dynamic programming algorithm for haplotype block partitioning , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Buetow,et al.  Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk , 1999, British Journal of Cancer.

[23]  S. P. Fodor,et al.  Blocks of Limited Haplotype Diversity Revealed by High-Resolution Scanning of Human Chromosome 21 , 2001, Science.

[24]  S. Andò,et al.  Aromatase overexpression enhances the stimulatory effects of adrenal androgens on MCF7 breast cancer cells , 2002, Molecular and Cellular Endocrinology.

[25]  R. Lewontin.  The Interaction of Selection and Linkage. I. General Considerations; Heterotic Models. , 1964, Genetics.

[26]  L. Excoffier,et al.  Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. , 1995, Molecular biology and evolution.

[27]  Pardis C Sabeti,et al.  Linkage disequilibrium in the human genome , 2001, Nature.

[28]  M. Pike,et al.  Endogenous hormones as a major factor in human cancer. , 1982, Cancer research.

[29]  C. Mendelson,et al.  Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. , 1991, Molecular endocrinology.

[30]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[31]  T. Key,et al.  Endogenous estrogen and postmenopausal breast cancer: a quantitative review , 1997, Cancer Causes & Control.

[32]  P. Goss,et al.  Aromatase inhibitors in the treatment and prevention of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Gardner,et al.  Carcinogenesis , 1961, The Yale Journal of Biology and Medicine.

[34]  O. Gotoh,et al.  Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. , 1997, Pharmacogenetics.

[35]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[36]  Deborah A. Nickerson,et al.  Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans , 2003, Nature Genetics.

[37]  M. Daly,et al.  High-resolution haplotype structure in the human genome , 2001, Nature Genetics.

[38]  A. Børresen-Dale,et al.  A rare CYP19 (aromatase) variant may increase the risk of breast cancer. , 1998, Pharmacogenetics.

[39]  A. V. Landeghem,et al.  Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. , 1985, Cancer research.

[40]  Peter H. Westfall,et al.  Testing Association of Statistically Inferred Haplotypes with Discrete and Continuous Traits in Samples of Unrelated Individuals , 2002, Human Heredity.

[41]  P. Jaeger,et al.  Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. , 1997, The Journal of clinical endocrinology and metabolism.

[42]  Nancy J. Cox,et al.  Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans , 1999, Nature Genetics.

[43]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  B. Ponder,et al.  Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. , 2000, Carcinogenesis.

[47]  N. Probst-Hensch,et al.  Aromatase and breast cancer susceptibility. , 1999, Endocrine-related cancer.